Skip to content

Study · Case report or series · n = 1 · 2018

1 result

Oxytocin and Gynecomastia: Correlation or Causality?

Amorim L, Gouveia FV, Germann J, Zambori D, Morais R, Sato FM, Fongaro C, Portolese J, Brentani H, Martinez R

Cureus21 May 2018Cited by 2 (Europe PMC)

PMID30042912 (opens in a new tab)PMCIDPMC6054360 (opens in a new tab)DOI10.7759/cureus.2661 (opens in a new tab)PepBankPUB-30042912
Download PDFPubMedAsk about this study
Jump to 1 result

Summary

Oxytocin has been administered to patients with autism spectrum disorder (ASD) in order to improve social skills, communication, and manage repetitive behaviors in the context of research trials. The majority of the studies focus on acute administration; thus, the effectiveness and potential side effects of chronic administration remain unknown. The main goal of this case report is to highlight the importance of the safety parameters for the chronic use of intranasal oxytocin administration. In a single case conducted in our outpatient clinic, one adolescent (15 years old) received intranasal oxytocin (24 IU) twice per day, in accordance with the recommended doses for this age group that varies from 8 - 25 IU twice per day. After three weeks of treatment, the patient presented with gynecomastia. While it is not certain that the gynecomastia was oxytocin-induced, this case highlights the importance of developing optimal regimens for chronic oxytocin administration, with a particular focus on safety parameters.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study1

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanCase report or seriesSafety outcome

    In one 15-year-old with autism spectrum disorder, gynecomastia appeared after three weeks of intranasal oxytocin; a causal link is not certain.

    In plain wordsIn one teenager given oxytocin nasal spray, breast enlargement appeared after three weeks. The case report cannot show that oxytocin caused it.

    Peptide
    Oxytocin
    Outcome
    IncreaseGynecomastia during chronic intranasal oxytocin
    Study

    n = 1

    Outcome group
    Adverse events · Endocrine and hormones
    Studied dose
    24 IU twice per day · intranasal · 3 weeksAs given in this study (human).

    Source sentences

    Summary
    After three weeks of treatment, the patient presented with gynecomastia.
    1 context sentence
    Summary · context
    In a single case conducted in our outpatient clinic, one adolescent (15 years old) received intranasal oxytocin (24 IU) twice per day, in accordance with the recommended doses for this age group that varies from 8 - 25 IU twice per day.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 01:30 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:48 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.